Mast Therapeutics (NASDAQ:SVRA) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Friday.
A number of other brokerages have also recently commented on SVRA. Zacks Investment Research cut Mast Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, November 23rd. Roth Capital reaffirmed a “buy” rating and set a $40.00 price objective on shares of Mast Therapeutics in a research note on Wednesday, September 27th. Finally, JMP Securities assumed coverage on Mast Therapeutics in a research note on Monday, September 11th. They set an “outperform” rating and a $20.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Mast Therapeutics has a consensus rating of “Buy” and a consensus price target of $21.30.
Mast Therapeutics (NASDAQ SVRA) traded up $0.54 during mid-day trading on Friday, hitting $13.49. The stock had a trading volume of 124,886 shares, compared to its average volume of 177,680. Mast Therapeutics has a 12 month low of $4.60 and a 12 month high of $16.10. The company has a quick ratio of 9.15, a current ratio of 9.15 and a debt-to-equity ratio of 0.20.
TRADEMARK VIOLATION WARNING: “Mast Therapeutics (SVRA) Downgraded by ValuEngine to Strong Sell” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/02/mast-therapeutics-svra-downgraded-by-valuengine-to-strong-sell.html.
Mast Therapeutics Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.